Q&A with Hans Engels, Business Unit President and CEO of DSM Pharmaceuticals - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Hans Engels, Business Unit President and CEO of DSM Pharmaceuticals

Pharmaceutical Technology
Volume 33, Issue 11

PharmTech:




What is the biggest industry challenge you're now facing?

Engels:

With the complexity we have in the supply chain for pharmaceutical products, it is absolutely necessary that the different elements of the supply chain interact much closer together than they have done in the past. Previously, a large pharmaceutical company controlled everything from the top down. By having enough excess capacity in all elements of the supply chain, they were able to fulfill the paradigm of always having product available in the marketplace.

Now this is going away. Now you have high-performing elements in your network that might be your own facility or might be somebody else's facility. You need to make sure that the information exchange between these elements in the network is flawless so that if there is any problem in one element of the network, everybody else becomes aware of it and can take appropriate action. The paradigm is still that product has to be available at all times in the marketplace. If you don't have product, that's the most costly failure you can have.

PharmTech:

A lot of people talk about just-in-time manufacturing, but do you think many pharmaceutical companies are actually trying to do it?

Engels:

If you want to apply it in the pharmaceutical industry, a lot of minds have to change. I think the pharmaceutical industry is far away from on-demand manufacturing for multiple reasons. One of the reasons is the culture of the industry, other reasons are compliance constraints. But I think this should not prevent us from getting as close as possible to that paradigm.

PharmTech:

Has DSM tried new ways of exchanging information with its clients?

Engels:

Yes. For instance, the whole supply chain must know about the progress of deviations in the quality system. We created a dashboard that tracks deviation handling throughout manufacturing, quality assurance, and the laboratories. Because we have not found a way to directly and securely tie clients into our systems, we created data rooms that are automatically updated so the customer can see data we have agreed upon up front that they want to see.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here